Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

10 healthy men will be PET-scanned (CNS) twice in random order with infusions of placebo or Native GLP-1 during hyperglycemic clamp to uncover the metabolic effects of GLP-1 in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Aarhus
• Treatments: Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• Informed consent signed

• Caucasian

• Male

• Age > 20 years and < 50 years

• BMI 20-30 kg/m² -

Exclusion Criteria:

Diabetes og first degree relative diabetes

• Clinically significant liver- or kidney-disease (se-ALAT > 2 times upper reference, or se-Creatinin > 130 mM

• Anemia

• Other abnormal biochemical value

• Any of the following:

• Heart disease

• Liver disease

• Kidney disease

• Lung disease

• Gastro-intestinal disease

• Dyslipidemia (total serum-cholesterol > 8 mmol/l, total cholesterol/HDL cholesterol ratio > 8 or se-triglyceride > 3.5 mmol/l)

• Endocrine disease (other than diabetes)

• CNS disease

• Hematological disease

• Loss of more than 100 ml blood within the latest month of inclusion

• Compliance problems

• Abuse of alcohol or drugs

• Smoking

• Participation in a clinical research study within 3 months of inclusion

• Allergy towards study hormones

• Medication with any drugs with effects on the glucose-metabolism, including *glitazones